HADHBは,大腸がんにおける5-フッ素ウラシルの感受性を媒介する
1Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Discover oncology
|August 28, 2025
まとめ
HADHBタンパク質の過剰発現は,大腸がん (CRC) の5フッ素ウラシル (5FU) 耐性に関連している. HADHB- DUOX2- ROS経路を標的とした治療は,CRC患者における5FU治療の有効性を改善する可能性がある.
科学分野:
- 腫瘍学
- 分子生物学
- 生物化学
背景:
- 5FUは結腸直腸がん (CRC) の基礎化学療法である.
- 特に5FUに対する薬剤耐性は,CRCにおける治療効果を著しく制限する.
- CRC内の5FU耐性におけるHydroxyacyl- CoAデヒドロゲネーゼβサブユニット (HADHB) の役割は十分に理解されていません.
研究 の 目的:
- 大腸がんにおける5FU感受性の調節におけるHADHBの役割を調査する.
- CRCにおける5FU耐性を克服するための治療標的としてのHADHBの可能性を決定する.
主な方法:
- 5FUの効能とHADHB発現を相関させるためのCRC組織の免疫ヒストキミカル分析.
- 細胞活性アッセイ (CCK-8) で,CRC細胞系における5FU IC50に対するHADHBの影響を評価する.
- コイムノプレシピテーション (Co-IP),光染色,フローサイトメトリーにより,HADHBと相互作用するタンパク質を特定し,活性酸素種 (ROS) レベルを測定する.
- メタボロミクスとトランスクリプトミクスで DUOX2に関連する代謝経路を調査します
主要な成果:
- 敏感組織と比較して,HADHB発現は5FU耐性CRC組織において有意に高かった.
- CRC細胞におけるHADHBのノックダウンは5FUの感受性を高め,アポトーシスを誘発し,細胞サイクル停止を引き起こした.
- DUOX2はHADHBと相互作用する新しいタンパク質として特定され,その相互作用はROSの産生を調節する.
- HADHB- DUOX2- ROS経路は5FUの感受性の調節に関与していた.
結論:
- HADHBの過剰発現は,大腸がんにおける5FU耐性に関連している.
- HADHB-DUOX2-ROS軸は5FU抵抗を誘発する潜在的なメカニズムを表しています.
- HADHBをターゲットにすることは,CRCにおける5FU耐性を克服するための実行可能な戦略である.
関連する概念動画
01:29Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
01:15Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
292
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
292
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264